Literature DB >> 8329303

Optic pathway/hypothalamic gliomas: a dilemma in management.

H J Hoffman1, R P Humphreys, J M Drake, J T Rutka, L E Becker, D Jenkin, M Greenberg.   

Abstract

Optic pathway gliomas follow an unpredictable course. Some remain static for years; others increase rapidly in size and often lead to death. This unpredictability, along with the histological similarity of these tumors, has resulted in controversy about their management. We have reviewed the results of management of all 62 patients with a diagnosis of optic pathway/hypothalamic glioma treated at The Hospital for Sick Children during the years 1976-1990. Twelve patients received no direct treatment, and 3 only a biopsy. Six patients were treated with radiotherapy alone. Eight patients received radiotherapy following a biopsy. Seventeen patients were treated by resection alone and 16 had a resection followed by radiotherapy. Eight patients received chemotherapy in addition to other therapy, and in 5 of them the chemotherapy was given as an initial therapy. Forty-eight patients are well with their visual deficits but 7 of them are receiving hormone replacement therapy. Six patients have significant neurologic deficits and 8 have died.

Entities:  

Mesh:

Year:  1993        PMID: 8329303     DOI: 10.1159/000120729

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  23 in total

1.  Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis.

Authors:  L Kornreich; S Blaser; M Schwarz; A Shuper; T H Vishne; I J Cohen; R Faingold; S Michovitz; B Koplewitz; G Horev
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

2.  Visual pathway glioma: an erratic tumour with therapeutic dilemmas.

Authors:  A Shuper; G Horev; L Kornreich; S Michowiz; R Weitz; R Zaizov; I J Cohen
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

Review 3.  Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature.

Authors:  Manolo Piccirilli; Jacopo Lenzi; Catia Delfinis; Guido Trasimeni; Maurizio Salvati; Antonino Raco
Journal:  Childs Nerv Syst       Date:  2006-04-26       Impact factor: 1.475

4.  Spontaneous regression of cerebellar astrocytoma after subtotal resection.

Authors:  Paul Steinbok; Ken Poskitt; Glenda Hendson
Journal:  Childs Nerv Syst       Date:  2006-03-16       Impact factor: 1.475

Review 5.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

6.  Long-term results of conventional treatment of diencephalic pilocytic astrocytoma in infants.

Authors:  Kazunori Arita; Kaoru Kurisu; Kazuhiko Sugiyama; Yoko Itoh; Takuhiro Hotta; Takashi Sogabe; Tohru Uozumi
Journal:  Childs Nerv Syst       Date:  2003-02-13       Impact factor: 1.475

7.  Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children.

Authors:  Ting-Rong Hsu; Tai-Tong Wong; Feng-Chi Chang; Donald M Ho; Ren-Bin Tang; Peck-Foong Thien; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2008-09-04       Impact factor: 1.475

Review 8.  Special issues in the management of gliomas in children with neurofibromatosis 1.

Authors:  I F Pollack; J J Mulvihill
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

10.  Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era.

Authors:  C Cappelli; J Grill; M Raquin; A Pierre-Kahn; A Lellouch-Tubiana; M J Terrier-Lacombe; J L Habrand; D Couanet; R Brauner; D Rodriguez; O Hartmann; C Kalifa
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.